{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.0","upperLimit":"6.5","value":"5.74"},{"groupId":"OG001","lowerLimit":"3.7","upperLimit":"12.9","value":"8.05"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"7"}],"units":"Participants"}],"description":"Progression-free survival was calculated as the time between the enrollment to the first documentation of progressive disease or death from any cause during study, whichever occurs earlier using the International Myeloma Working Group (IMWG) Uniform Response Criteria. Progressive Disease required increase of 25% from lowest response value in the serum M-component (absolute increase must be ≥ 0.5 g/dL) and/or urine M-component (absolute increase must be ≥ 200 mg/24 h).","dispersionType":"95% Confidence Interval","groups":[{"description":"Durvalumab 1500 mg + Daratumumab 16 mg/kg were administered intravenously within a 28-day cycle for a maximum of 60 cycles","id":"OG000","title":"Simon Stage 1: D2 Arm"},{"description":"Durvalumab 1500 mg IV + Daratumumab 16 mg/kg IV + Pomalidomide 4 mg/day Oral + Dexamethasone 40 mg Oral (20 mg for \\> 75 Years Old) were administered within a 28-day cycle for a maximum of 60 cycles","id":"OG001","title":"Simon Stage 1: D2 + Pomalidomide + Dexamethasone"}],"paramType":"MEDIAN","populationDescription":"All participants who received at least 1 dose of the study medications. Pre-specified for data to be collected only in D2 and D2 + Pomalidomide + Dexamethasone arms.","reportingStatus":"POSTED","timeFrame":"From enrollment to first documentation of progressive disease or death from any cause during study, whichever occurs earlier (up to approximately 66 months)","title":"Kaplan-Meier Estimate of Progression-Free Survival (PFS) - Simon Stage 1: D2 Arm","type":"SECONDARY","unitOfMeasure":"Months"}